Malignant hyperthermia nursing: recognition, dantrolene protocol, and NCLEX review

Malignant hyperthermia (MH) is a rare but potentially fatal pharmacogenetic disorder of skeletal muscle triggered by exposure to volatile halogenated anesthetic agents or the depolarizing neuromuscular blocking agent succinylcholine. Without immediate recognition and treatment, MH escalates from subtle metabolic changes to cardiovascular collapse, rhabdomyolysis, and death within minutes to hours. Even with optimal treatment, mortality remains approximately 3–5%.

For nurses working in the operating room, PACU, or any setting where anesthesia is administered, MH represents one of the highest-stakes clinical scenarios you will encounter. The nurse who recognizes the early signs — rising end-tidal CO2, unexplained tachycardia, masseter muscle rigidity — and activates the MH protocol immediately is the difference between a patient who survives and one who does not.

This guide covers the full clinical picture: pathophysiology, genetic basis, triggers vs. non-triggers, the step-by-step MHAUS emergency protocol, dantrolene reconstitution, post-crisis ICU monitoring, and how to counsel MH-susceptible patients and their families. Twenty NCLEX high-yield tips and five clinical tables are included.

Pathophysiology: what happens inside the muscle cell

Understanding MH at the cellular level makes the clinical presentation — and every treatment step — make intuitive sense.

Normal skeletal muscle contraction depends on tightly regulated calcium cycling. When a nerve impulse arrives, a voltage-sensing protein called the dihydropyridine receptor (DHPR, encoded by CACNA1S) detects membrane depolarization and triggers the ryanodine receptor type 1 (RYR1) to open on the sarcoplasmic reticulum membrane. Calcium floods into the cytoplasm, cross-bridges form between actin and myosin, and muscle shortens. When the signal stops, RYR1 closes and calcium pumps return it to the SR.

In MH-susceptible individuals, the RYR1 protein is abnormal — it is hyperresponsive to volatile halogenated anesthetics and succinylcholine. When these triggering agents are present, RYR1 stays open in an uncontrolled state. Calcium pours continuously into the cytoplasm without stopping. The result is a hypermetabolic skeletal muscle crisis:

• Sustained, unrelenting muscle contraction consumes massive amounts of ATP
• ATP regeneration via aerobic and anaerobic pathways drives extreme oxygen consumption, CO2 production, lactic acid generation, and heat production
• As intracellular calcium overwhelms the pump system, cell membranes fail
• Intracellular contents — potassium, myoglobin, creatine kinase — leak into the bloodstream
• Hyperkalemia, rhabdomyolysis, myoglobinuria, renal failure, disseminated intravascular coagulation (DIC), and cardiovascular collapse follow if the cycle is not broken

Dantrolene sodium works by directly inhibiting RYR1, blocking calcium release from the SR and interrupting the entire cascade. It is the only specific treatment for MH.

Genetic basis and susceptibility classification

MH is inherited in an autosomal dominant pattern with variable penetrance. A single copy of a mutated allele confers susceptibility. The key mutations are:

• RYR1 (ryanodine receptor type 1) — found on chromosome 19q13.2; responsible for the large majority of MH cases; more than 400 pathogenic variants identified
• CACNA1S (alpha-1 subunit of the DHPR voltage-sensor) — responsible for a minority of cases
• STAC3 — rare; associated with Native American myopathy

Patients are classified based on testing results:

A critical clinical fact: a negative genetic test does not exclude MH susceptibility. RYR1 variants are numerous, and panels do not capture all pathogenic mutations. A negative panel in a family with a known CHCT-positive member does not guarantee safety. Clinical management defaults to MH-safe precautions unless the specific family mutation is identified and the patient tests negative for that mutation.

Triggers vs. non-triggers: a life-or-death distinction

Knowing exactly which agents trigger MH — and which are safe — is fundamental nursing knowledge for any perioperative setting.

Clinical pearl: Nitrous oxide is often misidentified as a trigger because it is inhaled. It is not halogenated and has never been implicated in MH. Propofol TIVA (total intravenous anesthesia) with non-depolarizing NMBs is the standard MH-safe anesthetic plan.

Clinical presentation: early and late signs

MH is not a sudden collapse. It begins with subtle metabolic and muscle signs that escalate rapidly if unrecognized. The nurse who knows the early warning signs can activate the protocol before the patient enters the catastrophic phase.

Memory anchor: The mnemonic TRIMS captures the earliest signs — Tachycardia, Rising ETCO2, Increased muscle rigidity (masseter), Metabolic acidosis, Sharp temperature rise.

Masseter muscle rigidity: a special consideration

Masseter spasm after succinylcholine (sometimes called “succinylcholine-induced masseter spasm” or SIMS) requires immediate clinical judgment. Mild difficulty opening the jaw is common with succinylcholine and does not always indicate MH. Severe, sustained jaw stiffness — where the mouth cannot be opened to place an airway — is a red flag. In the context of rising ETCO2 or tachycardia, it should trigger immediate MH protocol activation.

Diagnosis: the Larach MH Clinical Grading Scale

MH diagnosis in an active crisis is primarily clinical — the anesthesia and nursing team cannot wait for laboratory confirmation. However, the Larach Clinical Grading Scale (1994) provides a validated, systematic approach to estimating the likelihood that a given anesthetic event represents MH.

The scale assigns weighted points across six clinical indicator categories, sums the raw score, and maps it to a rank from 1 (almost never MH) to 6 (almost certainly MH):

Rank interpretation:

• Rank 1 (raw score 0): almost never MH
• Rank 2 (raw score 3–9): unlikely MH
• Rank 3 (raw score 10–19): somewhat less than likely
• Rank 4 (raw score 20–34): somewhat greater than likely
• Rank 5 (raw score 35–49): very likely MH
• Rank 6 (raw score ≥50): almost certain MH

In clinical practice, a score in Rank 5 or 6 combined with exposure to a known trigger warrants full MH treatment regardless of laboratory confirmation.

Laboratory workup: ABG (low pH, high PaCO2, high lactate), serum CK (serial, every 4–6 hours), basic metabolic panel (potassium, creatinine, BUN), urine myoglobin and color, coagulation studies (PT, aPTT, fibrinogen, D-dimer).

MHAUS emergency protocol: step-by-step

The Malignant Hyperthermia Association of the United States (MHAUS) publishes the standard of care protocol for MH management. MHAUS also maintains a 24/7 hotline for live case management guidance: 1-800-MH-HYPER (1-800-644-9737).

Every step below should be executed simultaneously wherever possible. MH management is a team effort — call for help immediately and do not attempt this alone.

Step 1: call for help and activate the MH protocol

Announce MH emergency. Call the code or activate your institution’s MH protocol. Designate roles: one person for dantrolene preparation, one for cooling, one for medications, one for documentation. Call the MHAUS hotline.

Step 2: discontinue all triggering agents

Stop volatile anesthetic delivery immediately. Remove the vaporizer from the circuit if possible. Succinylcholine infusions must be stopped. If surgery must continue, maintain anesthesia using IV non-triggering agents (propofol infusion, opioids, benzodiazepines, non-depolarizing NMBs). Do not use volatile agents at any dose.

Step 3: hyperventilate with 100% oxygen

Increase fresh gas flow to ≥10 L/min with 100% oxygen. Hyperventilate to flush volatile agents from the circuit and begin correcting respiratory acidosis. Activated charcoal vapor filters can be placed on the inspiratory and expiratory limbs to adsorb residual volatile agent — they require replacement every 60 minutes. A clean, vaporizer-free breathing circuit is ideal if time permits.

Step 4: administer dantrolene sodium — STAT

Dantrolene is the only specific antidote for MH. Do not wait for temperature elevation to give dantrolene. Early administration before hyperthermia develops dramatically improves outcomes.

Dosing:

• Initial bolus: 2.5 mg/kg IV rapidly through the largest-bore IV available
• Repeat every 5 minutes as needed until: ETCO2 begins to fall, muscle rigidity decreases, heart rate stabilizes, or temperature starts to fall
• Most patients respond within 10 mg/kg total; doses exceeding 10 mg/kg may be required in patients with large muscle mass, prolonged exposure, or refractory cases — there is no absolute maximum
• Maintenance after crisis resolution: 1 mg/kg IV every 4–6 hours for 24–48 hours to prevent recrudescence

Step 5: reconstitute dantrolene correctly

Dantrolene reconstitution is a multi-person, time-critical task. Know the two available formulations:

MHAUS requirement: Facilities using volatile anesthetics must stock ≥36 vials of Dantrium/Revonto (720 mg) or an equivalent amount of Ryanodex accessible within 5 minutes of the anesthetizing location. This provides enough dantrolene to treat a 70 kg patient with approximately 10 mg/kg.

Step 6: active cooling

Begin cooling when core temperature exceeds 39°C — or immediately if it is rising rapidly:

• Ice packs to axillae, groin, and neck (areas of superficial large vessels)
• Cold IV saline infusion — use normal saline, NOT Ringer’s lactate (lactated Ringer’s adds lactate load to an already acidotic patient)
• Cooling blanket (surface)
• Gastric lavage with cold saline via NG tube for severe hyperthermia
• Bladder lavage with cold saline via Foley
• Stop active cooling when core temperature reaches 38°C to prevent iatrogenic hypothermia — dangerous undershoot is common if cooling is continued past this point

Step 7: treat arrhythmias

Arrhythmias in MH are typically driven by hyperkalemia, acidosis, and catecholamine surge. Use:

• Amiodarone — first-line for ventricular arrhythmias in this context
• Beta-blockers — acceptable if needed for rate control

CRITICAL: Do NOT use calcium channel blockers (verapamil, diltiazem). Calcium channel blockers combined with dantrolene can cause fatal cardiovascular collapse and hyperkalemia. This is an absolute contraindication.

Follow standard ACLS algorithms for rhythm management, with the exception above.

Step 8: treat severe acidosis

For pH <7.20 or base deficit >8 mEq/L:

• Sodium bicarbonate: 1–2 mEq/kg IV per dose
• Reassess ABG after each dose before repeating
• Hyperventilation alone will partially correct respiratory acidosis; bicarbonate addresses the metabolic component

Step 9: treat hyperkalemia

Hyperkalemia from rhabdomyolysis can cause fatal arrhythmias:

• Calcium gluconate (or calcium chloride): cardiac membrane stabilization — administer first if peaked T waves or K+ >6 mEq/L with ECG changes
• Regular insulin + dextrose: shifts K+ intracellularly (0.1 units/kg insulin IV with 25–50 g dextrose)
• Sodium bicarbonate: also shifts K+ intracellularly, addresses acidosis simultaneously
• Sodium polystyrene sulfonate (Kayexalate) works too slowly in acute crisis — not useful in immediate management

Step 10: place a Foley catheter and protect the kidneys

Insert a urinary catheter immediately if not already in place:

• Monitor urine output hourly — goal ≥1 mL/kg/hour (some guidelines cite ≥2 mL/kg/hour to promote myoglobin clearance)
• Monitor urine color — dark or cola-colored urine confirms myoglobinuria
• Aggressively fluid-resuscitate with IV normal saline to dilute myoglobin and maintain flow
• If oliguria persists despite fluids: furosemide or mannitol to force diuresis and prevent cast formation in renal tubules
• Monitor BUN, creatinine, and urine myoglobin serially

See AKI nursing for detailed management of myoglobin-induced acute kidney injury.

Step 11: transfer to ICU

Once the acute crisis is controlled, transfer to the intensive care unit for:

• Continued dantrolene maintenance (1 mg/kg IV every 4–6 hours × 24–48 hours)
• Serial monitoring of CK, electrolytes, renal function, coagulation every 4–6 hours
• Continued core temperature monitoring
• Vigilance for recrudescence (see Post-crisis monitoring, below)

The nursing role in MH: recognition to resolution

Nurses in perioperative and PACU settings are often the first clinicians to notice the early signs of MH. Understanding your specific role in each phase:

Pre-operative phase

• Review anesthetic history and flag MH-susceptible patients before the case begins
• Confirm MH cart location and that dantrolene stock is present and unexpired
• Know the MH emergency protocol for your facility
• Ensure the patient has disclosed any family history of anesthetic complications

Intraoperative phase (circulating or scrub nurse)

• Monitor the anesthesia monitor — rising ETCO2 is your first tip-off
• Observe for unexplained tachycardia on the cardiac monitor
• Note any difficulty placing an oral airway (masseter rigidity)
• If you see any early signs: say something immediately, call for help
• Once MH protocol is activated: your job is dantrolene preparation, documentation of each intervention with timestamp, cooling measures, and communication with the charge nurse and charge anesthesiologist

Documentation in an MH crisis

Accurate, timestamped documentation is essential — it drives dosing calculations (how much dantrolene has been given), guides the ICU team on post-crisis management, and supports medicolegal accountability. Document:

• Time first signs noted
• Time protocol activated
• Time each dantrolene bolus given and dose
• Temperature at each time point
• Every medication administered with dose, route, and time
• Urine output and color at each assessment
• All cooling interventions initiated and discontinued

Post-crisis monitoring in the ICU

MH does not end when the patient leaves the OR. Recrudescence — return of MH signs — occurs in approximately 20–30% of patients, typically within 4–8 hours of apparent resolution, but up to 24–48 hours later. Factors increasing risk include large muscle mass, prolonged anesthetic exposure (>150 minutes), and high triggering agent concentration.

ICU monitoring checklist:

• Dantrolene 1 mg/kg IV every 4–6 hours for minimum 24–48 hours — do not stop early
• Core temperature every 1–2 hours
• Serum CK every 4–6 hours — should be trending down; a rising CK suggests ongoing muscle injury or recrudescence
• Basic metabolic panel (K+, creatinine, BUN) every 4–6 hours
• Coagulation panel (PT, aPTT, fibrinogen, D-dimer) at least every 6–8 hours — DIC can develop or worsen
• Urine output hourly; urine color monitoring; consider urine myoglobin levels
• Continuous cardiac monitoring for arrhythmias
• Neurological assessments — prolonged hyperthermia can cause cerebral edema

Signs of recrudescence: rising core temperature, increasing muscle rigidity, rising ETCO2, worsening acidosis. If suspected: restart aggressive treatment, increase dantrolene dose, call MHAUS hotline.

Differential diagnosis: conditions that mimic MH

Several life-threatening conditions produce hyperthermia and/or rigidity and must be differentiated from MH quickly, because treatment differs significantly.

NMS vs MH — the critical distinction: Both cause hyperthermia and rigidity with potential for rhabdomyolysis and multi-organ failure. The clinical history differentiates them in most cases: MH requires anesthetic trigger exposure; NMS follows dopamine antagonist use and develops over hours to days. Mental status changes are typical in NMS but absent early in MH. Clonus and hyperreflexia point toward serotonin syndrome. Absent ETCO2 elevation in NMS/serotonin syndrome is an important point — rising ETCO2 during an anesthetic is essentially pathognomonic for MH.

MH susceptibility testing

Caffeine-halothane contracture test (CHCT)

The CHCT is the gold standard for confirming MH susceptibility. It is performed at specialized MH biopsy centers (approximately 15 in North America):

• A fresh muscle biopsy specimen (usually from the vastus lateralis of the thigh) is obtained under local or regional anesthesia — never volatile agents
• The live muscle strip is exposed to increasing concentrations of caffeine and halothane in an in vitro bath
• A contracture response at defined caffeine and halothane concentrations = MH susceptible (MHS)
• An intermediate response = MH equivocal (MHE), managed as susceptible
• No contracture response = MH non-susceptible (MHN) for that individual

CHCT has high sensitivity (~97%) and specificity (~78%). It is invasive, expensive, and requires travel to a biopsy center — but it is the definitive test for families where susceptibility must be confirmed or excluded.

Genetic testing

Genetic panels for RYR1 and CACNA1S pathogenic variants are available and increasingly accessible. Important limitations:

• A positive result confirms susceptibility — the patient should be managed as MHS
• A negative result does not exclude susceptibility — there are hundreds of RYR1 variants, and the panels do not capture all pathogenic mutations. Families with CHCT-positive members should not rely on a negative panel to declare a relative safe unless the specific family mutation is known and tested for

Genetic testing is useful for identifying at-risk family members when the proband’s mutation is known, and for avoiding unnecessary biopsy in those who test negative for a confirmed family mutation.

Patient and family counseling

MH susceptibility has lifelong and multigenerational implications. Nurses play a critical role in education and discharge planning after an MH event or new MH susceptibility diagnosis.

Key counseling points:

• MH is hereditary (autosomal dominant). Every first-degree relative — parents, siblings, children — has a 50% chance of inheriting the mutation and should be referred for MH susceptibility testing. Testing is coordinated through MHAUS or an anesthesiology genetics consultation.

• Medical alert identification. The patient should wear a medical alert bracelet or carry a medical alert card stating “MH susceptible — avoid volatile halogenated anesthetics and succinylcholine.” MHAUS provides wallet cards and bracelet information at mhaus.org.

• Every future anesthetic requires advance disclosure. The patient must inform every anesthesia provider before any surgical or procedural sedation — including dental procedures under general anesthesia, endoscopy, and emergency surgery. This includes providers outside their primary health system.

• MH-safe anesthetic plan. For all future procedures requiring general anesthesia, the standard plan is Total Intravenous Anesthesia (TIVA): propofol infusion + opioids + a non-depolarizing NMB (rocuronium, vecuronium, or cisatracurium). Regional anesthesia is preferred whenever feasible.

• Vaporizer-free, decontaminated circuit. Any anesthesia machine used for MHS patients must have vaporizers removed or disabled and must undergo a decontamination flush protocol before use. Simply turning off a vaporizer is not sufficient — residual volatile agent saturates the rubber components of the circuit.

• MHAUS resources. Patients and families should be referred to MHAUS (mhaus.org) for support, biopsy center referrals, patient education materials, and the 24/7 hotline.

• Exercise-induced MH. A small subset of MH-susceptible individuals can experience MH-like episodes during extreme exercise in hot environments (exertional heat stroke phenotype). Counsel patients to avoid extreme exertion in heat and to hydrate aggressively.

Connections to related nursing care

MH touches multiple nursing specialty areas. Understanding the connections strengthens your clinical picture:

• Perioperative nursing: MH prevention starts in pre-op. Identifying MH-susceptible patients and communicating to the anesthesia team before the case is standard pre-operative nursing practice.
• PACU nursing: Most MH events begin in the OR, but can present in the PACU. PACU nurses must know early MH signs and where the dantrolene cart is located in their unit.
• Cardiac arrhythmias nursing: MH triggers ventricular arrhythmias driven by hyperkalemia and acidosis. Understanding rhythm interpretation and the contraindication of calcium channel blockers is essential.
• Rhabdomyolysis nursing: MH causes one of the most severe forms of rhabdomyolysis. Fluid management, urine monitoring, and renal protection are shared skills.
• AKI nursing: Myoglobin-induced tubular injury from MH rhabdomyolysis is a major cause of AKI in the perioperative setting.
• Oxygen therapy nursing: High-flow 100% oxygen at ≥10 L/min is step 3 of the MHAUS protocol. Understanding flow rates and delivery systems matters here.
• Conscious sedation nursing: Procedural sedation settings must have MH protocols in place when volatile agents are used.

NCLEX high-yield: 20 tips for exam day

NCLEX scenario quick-reference

Summary: the MH nursing framework

Malignant hyperthermia is a pharmacogenetic emergency driven by uncontrolled sarcoplasmic reticulum calcium release in RYR1/CACNA1S-mutant skeletal muscle. The triggering agents are volatile halogenated anesthetics and succinylcholine — all other common anesthetic agents are safe.

The earliest signs are rising ETCO2 and unexplained tachycardia — temperature elevation comes later. Recognition and protocol activation within minutes is the variable that determines survival. Dantrolene at 2.5 mg/kg IV — reconstituted in sterile water, never saline — is the only specific treatment. Cooling stops at 38°C. Calcium channel blockers are absolutely contraindicated.

Post-crisis, patients require ICU monitoring for recrudescence for 24–48 hours. Every MH-susceptible patient and their first-degree relatives need genetic counseling, CHCT referral, medical alert identification, and a clear plan for MH-safe anesthesia in all future procedures.

Sources and further reading

• Malignant Hyperthermia Association of the United States (MHAUS): mhaus.org
• MHAUS Emergency Protocol: Managing a Crisis
• Larach MG et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80(4):771–779. PMID: 8024130
• Rosenberg H, Pollock N, Schiemann A, et al. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93. doi: 10.1186/s13023-015-0310-1
• Decker JA, Russo SG, Malignant Hyperthermia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. NBK430828
• European Malignant Hyperthermia Group. Recognising and managing a malignant hyperthermia crisis (v2024). emhg.org
• Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA. 2005;293(23):2918–2924